BioAlliance says partner Vestiq debuts Oravig in USA

8 January 2013

French biotech firm BioAlliance Pharma (Euronext Paris – BIO) has announces the launch of Oravig (miconazole buccal tablets, known as Loramyc in Europe) in the USA by its commercial partner, privately-held Vestiq Pharmaceuticals.

Just a few months after the signature of the license agreement between the two companies, worth a potential $44 million to BioAlliance (The Pharma Letter July 22, 2012), commercial teams have begun the active promotion of Oravig, a treatment for oropharyngeal candidiasis in adults, to US prescribers and wholesalers.

Based in North Carolina, Vestiq is a company dedicated to the commercialization of innovative, effective and safe therapeutic products designed to meet needs of patients requiring specific care. Following the recent acquisition of Praelia Pharmaceuticals by Vestiq, Oravig commercial operations will be driven directly by Praelia, the operational subsidiary. Vestiq has developed a specialized portfolio of therapeutic innovations dedicated to cancer supportive care, among which Oravig, indicated for the treatment of oropharyngeal candidiasis, holds a strategic position.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK